Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.

Abstract

Most patients with acute myeloid leukemia (AML) achieve complete remission (CR) after induction chemotherapy. Despite ensuing courses of consolidation chemotherapy, a large fraction of patients will experience relapses with poor prospects of long-term survival. Histamine dihydrochloride (HDC) in combination with the T-cell-derived cytokine IL-2 was recently approved within the EU as a remission maintenance immunotherapy in AML. HDC reduces myeloid cell-derived suppression of anti-leukemic lymphocytes, and aims to unravel a therapeutic benefit of IL-2 in AML by improving natural killer and T-cell activation. A randomized Phase III trial with 320 AML patients in CR demonstrated a significant reduction of relapse risk after immunotherapy with HDC plus low-dose IL-2 in the post-consolidation phase. HDC is the first approved therapeutic to target the state of immunosuppression in AML; further development in this area may comprise supplementary or alternative counter-suppressive agents with the aim to improve the efficacy of cancer immunotherapy.

• Authors: Anna Martner, Fredrik B Thorén, Johan Aurelius, Jonas Söderholm, Mats Brune, Kristoffer Hellstrand
• Journal: Expert review of hematology (Expert Rev Hematol) Vol. 3 Issue 4 Pg. 381-91 (Aug 2010) ISSN: 1747-4094 [Electronic] England
• PMID: 21083028 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Interleukin-2
• Histamine

Topics

• Antineoplastic Agents (adverse effects, immunology, therapeutic use)
• Histamine (adverse effects, immunology, therapeutic use)
• Humans
• Immunotherapy
• Interleukin-2 (adverse effects, immunology, therapeutic use)
• Leukemia, Myeloid, Acute (drug therapy)
• Molecular Targeted Therapy
• Secondary Prevention